Running chemotherapeutic drug screens on tumor biopsies ex vivo has the potential to increase patient survival by personally matching them to the drug which is the most effective against their particular tumor.
Researchers in Dr. Christina Smolke's lab have generated novel RNA aptamer sensors that can be used to regulate gene expression in response to the clinically relevant drug folinic acid.